Breast cancer is a malignant tumor that starts in breast tissue and is now the most commonly diagnosed cancer in women globally. Outcomes vary substantially by stage at diagnosis and access to timely treatment.
Greenwich LifeSciences received a second Nasdaq notice for late filing of its Form 10-Q, following a prior notice for a late Form 10-K. The company's stock continues trading on the Nasdaq Capital Market while it works to file the overdue reports.
Estrogen-only hormone replacement therapy after risk-reducing bilateral oophorectomy was associated with lower breast cancer risk in women with BRCA1 pathogenic variants. In 919 women followed for an average of 8.8 years, incident breast cancer was lower among HRT users than nonusers.
Cancer care is being transformed by targeted therapy, immunotherapy, personalized medicine, and emerging mRNA-based universal cancer vaccines. Advances in immunotherapeutics and cellular therapies are improving survival rates, while an off-the-shelf mRNA vaccine from the University of Florida is already in human trials.
The global antibody drug conjugate market is calculated at USD 14.76 billion in 2026 and is expected to reach USD 32.66 billion by 2035. North America held a 53% share in 2025, while Asia Pacific is projected to grow fastest.
More cancer survivors are living long enough to face lasting cardiovascular effects of treatment. Cardio-oncology clinics are managing heart failure, valvular disease and radiation-related heart disease.
FDA has accepted the NDA for vepdegestrant (ARV-471), an oral PROTAC ER degrader from Arvinas and Pfizer, for ESR1-mutated ER+/HER2- advanced breast cancer. A PDUFA date of June 5, 2026 has been set. The submission is based on positive Phase 3 VERITAC-2 data.
FDA's ODAC voted 6-3 against AstraZeneca's camizestrant for HR+/HER2- metastatic breast cancer, citing uncertain clinical benefit from the SERENA-6 trial design. The FDA raised concerns about the early-switch treatment paradigm and long-term outcomes.
Two studies show liquid biopsy can predict immunotherapy response in HER2-negative breast cancer and identify which patients with relapsed germ cell tumors may benefit from high-dose chemotherapy, advancing precision oncology.
January and March 2026 drug pipeline updates included Phase 3 results, Fast Track designations and Priority Review decisions across multiple disease areas. Mavacamten, teplizumab-mzwv, anifrolumab, AXS-05, gedatolisib and AFTX-201 were among the programs with notable milestones.
A $3.2 million research collaboration is developing a drug that directly breaks down MDM2 in triple-negative breast cancer. Early laboratory models showed tumour shrinkage, and the team is studying dosing, safety and performance.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07604441 |
Chemotherapy-Induced Peripheral Neuropathy - Additional Evaluation in Breast Cancer Survivors |
NOT_YET_RECRUITING | NA |
| NCT07604389 |
AR Health Education Video for Postoperative Breast Cancer Patients |
RECRUITING | NA |
| NCT07601152 |
Clinical and Biological Study of Early-onset Breast Cancer and the Influence of the Reproductive Cycle on the Aggressiveness of the Disease |
NOT_YET_RECRUITING | |
| NCT07599098 |
Effects of a Pilates Studio Program on Quality of Life and Functional Capacity of Women Undergoing Breast Cancer Treatment |
NOT_YET_RECRUITING | NA |
| NCT07597993 |
BEYOND Study: A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxtecan in Patients With HR Positive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated With Endocrine Therapy |
NOT_YET_RECRUITING | |
| NCT07597837 |
Oncoplastic Surgery Outcomes Database |
RECRUITING | |
| NCT07596472 |
Ultrasound Monitoring of Clipped Lymph Nodes to Predict Axillary Response After Chemotherapy in Breast Cancer |
NOT_YET_RECRUITING | |
| NCT07596459 |
Hybrıd Educatıon Based on Psychodynamıc Nursıng Theory of Women Undergoıng Mastectomy |
COMPLETED | NA |
| NCT07596212 |
BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07593976 |
Evaluation of [68Ga]Ga-NOTA-anti-HER2-sdAb PET/CT for Predicting Pathological Complete Response After Neoadjuvant Chemotherapy in HER2 Positive Early Breast Cancer |
NOT_YET_RECRUITING | PHASE2 |
